Viridian Therapeutics, Inc.
VRDN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $302 | $314 | $1,772 | $2,963 |
| % Growth | -3.8% | -82.3% | -40.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $302 | $314 | $1,772 | $2,963 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $238,254 | $159,765 | $100,894 | $56,886 |
| G&A Expenses | $61,083 | $94,999 | $35,182 | $25,805 |
| SG&A Expenses | $61,083 | $94,999 | $35,182 | $25,805 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $299,337 | $254,764 | $136,076 | $82,691 |
| Operating Income | -$299,035 | -$254,450 | -$134,304 | -$79,728 |
| % Margin | -99,018.2% | -81,035% | -7,579.2% | -2,690.8% |
| Other Income/Exp. Net | $29,086 | $16,716 | $4,430 | $315 |
| Pre-Tax Income | -$269,949 | -$237,734 | -$129,874 | -$79,413 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$269,949 | -$237,734 | -$129,874 | -$79,413 |
| % Margin | -89,387.1% | -75,711.5% | -7,329.2% | -2,680.2% |
| EPS | -3.98 | -5.31 | -3.91 | -6.66 |
| % Growth | 25% | -35.8% | 41.3% | – |
| EPS Diluted | -3.98 | -5.31 | -3.91 | -6.66 |
| Weighted Avg Shares Out | 67,886 | 44,755 | 32,087 | 11,919 |
| Weighted Avg Shares Out Dil | 67,886 | 44,755 | 32,087 | 11,919 |
| Supplemental Information | – | – | – | – |
| Interest Income | $32,132 | $18,563 | $4,916 | $318 |
| Interest Expense | $3,046 | $1,847 | $486 | $3 |
| Depreciation & Amortization | $1,240 | $522 | $255 | $120 |
| EBITDA | -$265,663 | -$235,365 | -$129,133 | -$79,290 |
| % Margin | -87,967.9% | -74,957% | -7,287.4% | -2,676% |